
Sign up to save your podcasts
Or


This week, we're hearing about three reports on genitourinary cancers presented at ESMO Virtual Congress 2020. We'll hear directly from the researchers about first-line treatment for metastatic renal cell carcinoma, as well as the long-term results of a doublet therapy for men with advanced hormone-naive prostate cancer.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we're hearing about three reports on genitourinary cancers presented at ESMO Virtual Congress 2020. We'll hear directly from the researchers about first-line treatment for metastatic renal cell carcinoma, as well as the long-term results of a doublet therapy for men with advanced hormone-naive prostate cancer.
By BroadcastMed4.5
1515 ratings
This week, we're hearing about three reports on genitourinary cancers presented at ESMO Virtual Congress 2020. We'll hear directly from the researchers about first-line treatment for metastatic renal cell carcinoma, as well as the long-term results of a doublet therapy for men with advanced hormone-naive prostate cancer.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we're hearing about three reports on genitourinary cancers presented at ESMO Virtual Congress 2020. We'll hear directly from the researchers about first-line treatment for metastatic renal cell carcinoma, as well as the long-term results of a doublet therapy for men with advanced hormone-naive prostate cancer.